Jasia Mahdi

Baylor College of Medicine — United States

Medicine · Health Sciences

9h-index1.3kcitations39works7.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(16), CAR-T cell therapy research(16), Immunotherapy and Immune Responses(4), Neurofibromatosis and Schwannoma Cases(4), Meningioma and schwannoma management(3)

Publications39 total

Response Assessment in Pediatric Neuro-Oncology (RAPNO) Symposium, Pediatric Society of Neuro-Oncology Proceedings: Current Status and Future Initiatives
Neuro-Oncology Pediatrics·2026Open Access
BIOM-107. EVALUATION OF B7-H3 IMMUNOHISTOCHEMISTRY IN HIGH-GRADE GLIOMAS FOR CHIMERIC ANTIGEN RECEPTOR T-CELL PREDICTIVE TESTING
Neuro-Oncology·2025Open Access
269 Humanized anti-CAR antibodies affect durable response to GD2-CAR T-cells in diffuse midline glioma
Regular and Young Investigator Award Abstracts·2025Open Access
CTP-07. Phase I study of intravenous and intracerebroventricular C7R-GD2.CAR T cell therapy for pediatric central nervous system (CNS) tumors
Neuro-Oncology·2025Open Access
SURP-01. Clinical Impact of Intratumoral Cyst Decompression in Diffuse Intrinsic Pontine Glioma Patients: A Retrospective Analysis
Neuro-Oncology·2025Open Access
CTIM-05. HUMANIZED ANTI-CAR ANTIBODIES AFFECT DURABLE RESPONSE TO GD2-CAR T-CELLS IN DIFFUSE MIDLINE GLIOMA
Neuro-Oncology·2025Open Access
EPCO-45. SINGLE-CELL LANDSCAPE OF B7H3-CAR T THERAPY IN GLIOMA: MECHANISMS OF RESISTANCE AND SIGNATURES OF LONG-TERM RESPONSE
Neuro-Oncology·2025
Neurotoxicity in central nervous system tumors treated with CAR T cell therapy: a review
Journal of Neuro-Oncology·2025· 1 cited
The promise of immunotherapy for central nervous system tumours
Nature reviews. Immunology·2025· 3 cited
The DIPG/DMG National Tumor Board: The power of advocacy
Neuro-Oncology Pediatrics·2025Open Access
Point/counterpoint: Upfront BRAF inhibition for adult BRAF-mutant high-grade gliomas
Neuro-Oncology·2025Open Access
A great mitigator of non-ICANS neurotoxicities?
Blood·2025Open Access
A phase 1 study of B7H3 CAR-T cells administered intracranially in recurrent glioblastoma.
Journal of Clinical Oncology·2025· 3 cited
Abstract 7123: Unravelling temporal dynamics of GD2-CAR T cell therapy in H3K27M-mutant diffuse midline glioma through comprehensive single-cell and multi-omic profiling
Cancer Research·2025
Author Correction: Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Nature·2024· 12 citedOpen Access
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas
Nature·2024· 126 citedOpen Access
IMMU-60. MYELOID POPULATIONS MODULATE GD2 CAR T CELL ACTIVITY IN DIFFUSE MIDLINE GLIOMA
Neuro-Oncology·2024· 1 citedOpen Access
NCOG-46. CHROMOSOMAL LOSSES CORRELATE WITH POOR OVERALL SURVIVAL IN H3K27M-ALTERED DIFFUSE MIDLINE GLIOMAS
Neuro-Oncology·2024Open Access
Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomas
2024· 6 citedOpen Access
IMMU-13. TUMOR INFLAMMATION-ASSOCIATED NEUROTOXICITY (TIAN): A TOXICITY SYNDROME IN PATIENTS TREATED WITH IMMUNOTHERAPY FOR CENTRAL NERVOUS SYSTEM TUMORS
Neuro-Oncology·2024Open Access
page 1 of 2Next →

Frequent Co-authors

Michelle Monje(26), Sneha Ramakrishna(21), Sonia Partap(18), Cynthia Campen(18), Bita Sahaf(18), Robbie G. Majzner(17), Liora M. Schultz(17), Emily Egeler(17), Kara L. Davis(17), Rebecca M. Richards(15), Sharon Mavroukakis(14), Jennifer Moon(14), Valentin Barsan(13), Christina Baggott(13), Steven A. Feldman(13), Courtney Erickson(12), Michael Kunicki(12), Michelle Fujimoto(12), Zachary Ehlinger(12), Snehit Prabhu(11)